Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2008 Nov 11:337:a2423.
doi: 10.1136/bmj.a2423.

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

Jorie Versmissen  1 , Daniëlla M Oosterveer, Mojgan Yazdanpanah, Joep C Defesche, Dick C G Basart, Anho H Liem, Jan Heeringa, Jacqueline C Witteman, Peter J Lansberg, John J P Kastelein, Eric J G Sijbrands
Affiliations
Multicenter Study

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

Jorie Versmissen et al. BMJ. .

Abstract

Objective: To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia.

Design: Cohort study with a mean follow-up of 8.5 years.

Setting: 27 outpatient lipid clinics.

Subjects: 2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990.

Main outcome measures: Risk of coronary heart disease in treated and "untreated" (delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable.

Results: In January 1990, 413 (21%) of the patients had started statin treatment, and during follow-up another 1294 patients (66%) started after a mean delay of 4.3 years. Most patients received simvastatin (n=1167, 33 mg daily) or atorvastatin (n=211, 49 mg daily). We observed an overall risk reduction of 76% (hazard ratio 0.24 (95% confidence interval 0.18 to 0.30), P<0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age-matched sample from the general population (hazard ration 1.44 (0.80 to 2.60), P=0.23).

Conclusion: Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

None
Fig 1 Flow of patients through study
None
Fig 2 Kaplan-Meier curve estimates of cumulative coronary heart disease-free survival among patients with familial hypercholesterolaemia according to statin treatment (P<0.001 for difference)
None
Fig 3 Subgroup analyses for reduction in risk of coronary heart disease in patients with familial hypercholesterolaemia by statin use in a time dependent analysis. Smoking, diabetes, and hypertension were compared based on having ever been present. LDL cholesterol concentration was split based on the median value, and HDL cholesterol level split based on normal laboratory values. Hazard ratio (95% CI) by statin use is shown on a logarithmic scale
None
Fig 4 Kaplan-Meier curve estimates of cumulative myocardial infarct-free survival among patients with familial hypercholesterolaemia older than 55 years according to statin treatment compared with a sample from the general population (Rotterdam study). (P<0.001 for difference between untreated patients and general population; P=0.07 for difference between treated patients and general population)
See this image and copyright information in PMC

Comment in

References

    1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Familial hypercholesterolemia and coronary heart disease: a HuGE association review. Am J Epidemiol 2004;160:421-9. - PubMed
    1. National Institute for Health and Clinical Excellence. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. 2008 (Clinical guideline 71) www.nice.org.uk/CG71
    1. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003;168:1-14. - PubMed
    1. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81. - PubMed
    1. Van Wissen S, Smilde TJ, Trip MD, Stalenhoef AF, Kastelein JJ. Long term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia. Am J Cardiol 2005;95:264-6. - PubMed

Publication types